阐明胶质细胞对糖尿病相关全身稳态失调产物的反应
糖尿病视网膜病变(DR)是工作年龄成人致盲的主要原因,全身因素如血糖控制不佳、高血压和高脂血症增加DR进展风险。本文综述正常胶质细胞功能及其在DR中的可能作用,描述胶质细胞转录组对高血糖中葡萄糖、高血压中血管紧张素II和高脂血症中游离脂肪酸棕榈酸的反应,并讨论以胶质细胞为DR治疗靶点的益处与挑战。
要点
- 胶质细胞介导稳态与修复,可能协调视网膜病变全程的事件。
- 体外刺激提示星形胶质细胞可能比其他胶质细胞对全身稳态失调产物更敏感。
- 高血糖对胶质细胞的作用可能主要是渗透性的。
核心结论
- 理解胶质细胞对糖尿病相关全身稳态失调产物的反应可能揭示DR病理生理学的新见解,并指导开发新疗法。
- 虽然许多与DR病理生理学相关的分子在本综述中得到验证,但一些较少探索的分子成为潜在治疗靶点。
- 未来表征胶质细胞在DR中的作用及其激活如何被调节和维持的研究,可能有助于阐明DR发病机制并识别新药物靶点。
研究设计与样本
- 本文为综述,回顾正常胶质细胞功能及其在DR中的可能作用,描述胶质细胞转录组对全身循环因素的反应,并讨论以胶质细胞为DR治疗靶点的益处与挑战。
主要发现
- 体外用葡萄糖、血管紧张素II和棕榈酸刺激胶质细胞提示星形胶质细胞可能比其他胶质细胞对这些全身稳态失调产物更敏感。
- 体外刺激提示高血糖对胶质细胞的作用可能主要是渗透性的。
- 体外刺激提示脂肪酸积累可能主要通过促进大胶质细胞和小胶质细胞的促炎和促血管生成转录改变来加重DR病理生理学。
- 体外刺激提示细胞靶向疗法可能通过规避视网膜细胞反应多效性这一复杂问题,为DR治疗提供更安全和更有效的途径。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,未来表征胶质细胞在DR中的作用及其激活如何被调节和维持的研究,可能有助于阐明DR发病机制并识别新药物靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic retinopathy (DR) is a leading cause of blindness in working age adults. DR has non-proliferative stages, characterized in part by retinal neuroinflammation and ischemia, and proliferative stages, characterized by retinal angiogenesis. Several systemic factors, including poor glycemic control, hypertension, and hyperlipidemia, increase the risk of DR progression to vision-threatening stages. Identification of cellular or molecular targets in early DR events could allow more prompt interventions pre-empting DR progression to vision-threatening stages. Glia mediate homeostasis and repair. They contribute to immune surveillance and defense, cytokine and growth factor production and secretion, ion and neurotransmitter balance, neuroprotection, and, potentially, regeneration. Therefore, it is likely that glia orchestrate events throughout the development and progression of retinopathy. Understanding glial responses to products of diabetes-associated systemic dyshomeostasis may reveal novel insights into the pathophysiology of DR and guide the development of novel therapies for this potentially blinding condition. In this article, first, we review normal glial functions and their putative roles in the development of DR. We then describe glial transcriptome alterations in response to systemic circulating factors that are upregulated in patients with diabetes and diabetes-related comorbidities; namely glucose in hyperglycemia, angiotensin II in hypertension, and the free fatty acid palmitic acid in hyperlipidemia. Finally, we discuss potential benefits and challenges associated with studying glia as targets of DR therapeutic interventions. In vitro stimulation of glia with glucose, angiotensin II and palmitic acid suggests that: 1) astrocytes may be more responsive than other glia to these products of systemic dyshomeostasis; 2) the effects of hyperglycemia on glia are likely to be largely osmotic; 3) fatty acid accumulation may compound DR pathophysiology by promoting predominantly proinflammatory and proangiogenic transcriptional alterations of macro and microglia; and 4) cell-targeted therapies may offer safer and more effective avenues for DR treatment as they may circumvent the complication of pleiotropism in retinal cell responses. Although several molecules previously implicated in DR pathophysiology are validated in this review, some less explored molecules emerge as potential therapeutic targets. Whereas much is known regarding glial cell activation, future studies characterizing the role of glia in DR and how their activation is regulated and sustained (independently or as part of retinal cell networks) may help elucidate mechanisms of DR pathogenesis and identify novel drug targets for this blinding disease.
引用
- Padovani-Claudio DA, Ramos CJ, Capozzi ME, et al. Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis. Prog Retin Eye Res. 2023. PMID: 37028118. doi:10.1016/j.preteyeres.2022.101151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。